Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...
By Dr. Liji Thomas, MD By merging voice instability, gait asymmetry, and tremor-driven handwriting changes into a single explainable AI framework, researchers show how digital biomarkers can move ...
NORTH CHICAGO, Ill., Dec. 2, 2025 /PRNewswire/ -- AbbVie today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research ...
Additional oral presentations explore odronextamab in areas of high unmet need, including the primary analysis in diffuse large B-cell lymphoma progressing after CAR-T therapy and first results in ...